Managing irritable bowel syndrome

American Journal of Nursing

Volumn 113, Issue 7, 2013, Pages 42-52

  Anastasi, Joyce K ^a   Capili, Bernadette ^a   Chang, Michelle ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Constipation; Diarrhea; Gastrointestinal; Irritable bowel syndrome; Symptom management

Indexed keywords

ADULT; ARTICLE; DIET THERAPY; FEMALE; HUMAN; IRRITABLE COLON; LIFESTYLE; PATHOPHYSIOLOGY;

ADULT; DIET THERAPY; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LIFE STYLE;

EID: 84880428370     PISSN: 0002936X     EISSN: 15387488     Source Type: Journal    
DOI: 10.1097/01.NAJ.0000431911.65473.35     Document Type: Article

References (116)

1. .American College of Gastroenterology Task Force on Irrita-ble Bowel Syndrome, et al. An evidence-based position state-ment on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-S35
2. Andrews EB, et al. Prevalence and demographics of irritable bowel syndrome: Results from a large web-based survey. Aliment Pharmacol Ther 2005;22(10):935-42
3. Drossman D, ed. Rome III: The functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates; 2006
4. Lovell RM, Ford AC. Effect of gender on prevalence of ir-ritable bowel syndrome in the community: Systematic re-view and meta-Analysis. Am J Gastroenterol 2012;107(7): 991-1000
5. Whitehead WE, et al. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002;122(4): 1140-56
6. Agarwal N, Spiegel BM. The effect of irritable bowel syn-drome on health-related quality of life and health care ex-penditures. Gastroenterol Clin North Am 2011;40(1):11-9
7. Inadomi JM, et al. Systematic review: The economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18(7):671-82
8. Longstreth GF, et al. Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003;98(3):600-7
9. Spiegel BM. The burden of IBS: Looking at metrics. Curr Gastroenterol Rep 2009;11(4):265-9
10. DiBonaventura M, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011;27(11):2213-22
11. Drossman DA, et al. International survey of patients with IBS: Symptom features and their severity, health status, treat-ments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43(6):541-50
12. American Gastroenterological Association. The burden of gastrointestinal diseases. Bethesda, MA; 2001. http://www. lewin.com/~/media/lewin/site-sections/ publications/2695. pdf
13. Chang JY, Talley NJ. An update on irritable bowel syn-drome: From diagnosis to emerging therapies. Curr Opin Gastroenterol 2011;27(1):72-8
14. Ohman L, Simren M. Pathogenesis of IBS: Role of inflamma-Tion, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7(3):163-73
15. Simrén M, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013;62(1): 159-76
16. Ford AC, et al. Small intestinal bacterial overgrowth in irri-Table bowel syndrome: Systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2009;7(12):1279-86
17. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: Role of genetics, immune activation, sero-Tonin and altered microbiome. J Neurogastroenterol Motil 2012;18(3):258-68
18. Ford AC, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syn-drome: Systematic review and meta-Analysis. Arch Intern Med 2009;169(7):651-8
19. Kalantar JS, et al. Familial aggregation of irritable bowel syndrome: A prospective study. Gut 2003;52(12):1703-7
20. Saito YA, et al. Irritable bowel syndrome aggregates strongly in families: A family-based case-control study. Neurogastroenterol Motil 2008;20(7):790-7
21. Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am 2011;40(1):45-67
22. Gros DF, et al. Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disord 2009;23(2):290-6
23. Ladabaum U, et al. Diagnosis, comorbidities, and manage-ment of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 2012; 10(1):37-45
24. Locke GR, 3rd, et al. Psychosocial factors are linked to func-Tional gastrointestinal disorders: A population based nested case-control study. Am J Gastroenterol 2004;99(2):350-7
25. Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psy-chological treatments. Gastroenterol Clin North Am 2005; 34(2):281-303
26. Whitehead WE, et al. Comorbidity in irritable bowel syn-drome. Am J Gastroenterol 2007;102(12):2767-76
27. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011;140(3):761-5
28. Choung RS, et al. Psychosocial distress and somatic symp-Toms in community subjects with irritable bowel syndrome: A psychological component is the rule. Am J Gastroenterol 2009;104(7):1772-9
29. Camilleri M. Do the symptom-based, Rome criteria of irri-Table bowel syndrome lead to better diagnosis and treatment outcomes? The con argument. Clin Gastroenterol Hepatol 2009;8(2):129
30. Camilleri M. Irritable bowel syndrome: How useful is the term and the 'diagnosis'? Therap Adv Gastroenterol 2012; 5(6):381-6
31. Laine C, et al. In the clinic: Irritable bowel syndrome. Ann Intern Med 2007;147(1):ITC7-1-ITC7-16
32. Lucak S. Diagnosing irritable bowel syndrome: What's too much, what's enough? MedGenMed 2004;6(1):17
33. Marshall JK, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attrib-uted to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5(4):457-60
34. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136(6):1979-88
35. Talley NJ, et al. Overlapping upper and lower gastrointesti-nal symptoms in irritable bowel syndrome patients with con-stipation or diarrhea. Am J Gastroenterol 2003;98(11): 2454-9
36. Lembo TJ, Fink RN. Clinical assessment of irritable bowel syndrome. J Clin Gastroenterol 2002;35(1 Suppl):S31-S36
37. Cash BD, et al. The utility of diagnostic tests in irritable bowel syndrome patients: A systematic review. Am J Gastroenterol 2002;97(11):2812-9
38. Spiegel BM, et al. Is irritable bowel syndrome a diagnosis of exclusion?: A survey of primary care providers, gastroenterolo-gists, and IBS experts. Am J Gastroenterol 2010;105(4): 848-58
39. American College of Gastroenterology. Understanding irritable bowel syndrome. 2003. http://patients.gi.org/gi-health-And-disease/understanding- irritable-bowel-syndrome
40. Whitehead WE, et al. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(11-12): 1305-15
41. De Schryver AM, et al. Effects of regular physical activity on defecation pattern in middle-Aged patients complaining of chronic constipation. Scand J Gastroenterol 2005;40(4): 422-9
42. Johannesson E, et al. Physical activity improves symptoms in irritable bowel syndrome: A randomized controlled trial. Am J Gastroenterol 2011;106(5):915-22
43. Villoria A, et al. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol 2006;101(11): 2552-7
44. Herring MP, et al. The effect of exercise training on anxiety symptoms among patients: A systematic review. Arch Intern Med 2010;170(4):321-31
45. Rimer J, et al. Exercise for depression. Cochrane Database Syst Rev 2012;7:CD004366
46. Heizer WD, et al. The role of diet in symptoms of irritable bowel syndrome in adults: A narrative review. J Am Diet Assoc 2009;109(7):1204-14
47. Shepherd SJ, et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008;6(7):765-71
48. Biesiekierski JR, et al. Gluten causes gastrointestinal symp-Toms in subjects without celiac disease: A double-blind ran-domized placebo-controlled trial. Am J Gastroenterol 2011; 106(3):508-14
49. Bahar RJ, et al. Double-blind placebo-controlled trial of am-itriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008;152(5):685-9
50. Camilleri M, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161(14):1733-40
51. Chey WD, et al. Long-Term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99(11):2195-203
52. Drossman DA. Beyond tricyclics: New ideas for treating pa-Tients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 2009;104(12):2897-902
53. Drossman DA, et al. Clinical trial: Lubiprostone in patients with constipation-Associated irritable bowel syndrome -results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29(3):329-41
54. Drossman DA, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125(1):19-31
55. Ford AC, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-Analysis. Am J Gastroenterol 2009;104(7):1831-43
56. Ford AC, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-Analysis. Gut 2009;58(3):367-78
57. Khoshoo V, et al. Effect of a laxative with and without tega-serod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23(1):191-6
58. Krause R, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102(8):1709-19
59. Ladabaum U, et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010;8(1):42-8.e1
60. Lembo AJ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials. Clin Gastroenterol Hepatol 2004;2(8):675-82
61. Masand PS, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 2009;50(1):78-86
62. Pimentel M, et al. Rifaximin therapy for patients with irrita-ble bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32
63. Pimentel M, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med 2006;145(8):557-63
64. Prometheus Laboratories. Highlights of prescribing information: Lotronex (alosetron hydrochloride) tablets. San Diego; 2010. http://www.accessdata.fda. gov/drugsatfda-docs/label/ 2010/021107s016lbl.pdf
65. Saad RJ. Peripherally acting therapies for the treatment of irritable bowel syndrome. Gastroenterol Clin North Am 2011;40(1):163-82
66. Sainsbury A, Ford AC. Treatment of irritable bowel syn-drome: Beyond fiber and antispasmodic agents. Therap Adv Gastroenterol 2011;4(2):115-27
67. Sharara AI, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloat-ing and flatulence. Am J Gastroenterol 2006;101(2):326-33
68. Tack J, et al. A controlled crossover study of the selective se-rotonin reuptake inhibitor citalopram in irritable bowel syn-drome. Gut 2006;55(8):1095-103
69. Takeda Pharmaceuticals America. Highlights of prescribing information: Amitiza (lubiprostone) capsules. Deerfield, IL; 2012. http://www.accessdata.fda. gov/drugsatfda-docs/label/ 2012/021908s010lbl.pdf
70. U.S. Food and Drug Administration. Zelnorm (tegaserod maleate) information. Silver Spring, MD; 2007. http://www. fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInforma tionforPatientsandProviders/ucm103223.htm
71. Vahedi H, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22(5):381-5
72. Watson ME, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96(2):455-9
73. Brandt LJ, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100 Suppl 1:S5-S21
74. Ruepert L, et al. Bulking agents, antispasmodics and antide-pressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011(8):CD003460
75. Chey WD, et al. Safety and patient outcomes with lubipros-Tone for up to 52 weeks in patients with irritable bowel syn-drome with constipation. Aliment Pharmacol Ther 2012; 35(5):587-99
76. U.S. Food and Drug Administration. NME drug and new biologic approvals in 2002. Silver Spring, MD; 2002
77. Chang HY, et al. Current gut-directed therapies for irritable bowel syndrome. Curr Treat Options Gastroenterol 2006; 9(4):314-23
78. Bleser S. Alosetron for severe diarrhea-predominant irritable bowel syndrome: Improving patient outcomes. Curr Med Res Opin 2011;27(3):503-12
79. Dekel R, et al. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs 2013;22(3): 329-39
80. Vahedi H, et al. Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syn-drome. Aliment Pharmacol Ther 2008;27(8):678-84
81. Drossman DA, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999;45 Suppl 2:II25-II30
82. Zijdenbos IL, et al. Psychological treatments for the man-Agement of irritable bowel syndrome. Cochrane Database Syst Rev 2009(1):CD006442
83. Lackner JM, et al. Psychological treatments for irritable bowel syndrome: A systematic review and meta-Analysis. J Consult Clin Psychol 2004;72(6):1100-13
84. Lackner JM, et al. Rapid response to cognitive behavior ther-Apy predicts treatment outcome in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010;8(5): 426-32
85. Jarrett ME, et al. Comprehensive self-management for irrita-ble bowel syndrome: Randomized trial of in-person vs. com-bined in-person and telephone sessions. Am J Gastroenterol 2009;104(12):3004-14
86. Palsson OS, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: A primer for the gastro-enterologist. Clin Gastroenterol Hepatol 2013;11(3):208-16
87. Wilson S, et al. Systematic review: The effectiveness of hyp-notherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24(5):769-80
88. Smith GD. Effect of nurse-led gut-directed hypnotherapy upon health-related quality of life in patients with irritable bowel syndrome. J Clin Nurs 2006;15(6):678-84
89. Chapman W. Hypnotherapy as a treatment for irritable bowel syndrome. Gastrointestinal Nursing 2004;2(2):23-8
90. Giese LA. A study of alternative health care use for gastroin-Testinal disorders. Gastroenterol Nurs 2000;23(1):19-27
91. Koloski NA, et al. Predictors of conventional and alterna-Tive health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2003;17(6): 841-51
92. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013;29(2):184-9
93. O'Mahony L, et al. Lactobacillus and bifidobacterium in irri-Table bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128(3):541-51
94. Whorwell PJ, et al. Efficacy of an encapsulated probiotic Bifi-dobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(7):1581-90
95. Cappello G, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: A prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39(6):530-6
96. Liu JH, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, ran-domized trial. J Gastroenterol 1997;32(6):765-8
97. Merat S, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010;55(5):1385-90
98. Therapeutic Research Faculty. Natural medicines comprehensive database: Peppermint oil. 2012. http://www. naturaldatabase.com
99. Ezzo JM, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006(2):CD002285
100. Lee A, Fan LT. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2009(2):CD003281
101. Wang SM, et al. Acupuncture analgesia: I. The scientific basis. Anesth Analg 2008;106(2):602-10
102. Goldman N, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 2010;13(7):883-8
103. Hui KK, et al. The integrated response of the human cerebro-cerebellar and limbic systems to acupuncture stimulation at ST 36 as evidenced by fMRI. Neuroimage 2005;27(3): 479-96
104. Fireman Z, et al. Acupuncture treatment for irritable bowel syndrome. A double-blind controlled study. Digestion 2001; 64(2):100-3
105. Forbes A, et al. Acupuncture for irritable bowel syndrome: A blinded placebo-controlled trial. World J Gastroenterol 2005;11(26):4040-4
106. Lembo AJ, et al. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009;104(6):1489-97
107. Schneider A, et al. Acupuncture treatment in irritable bowel syndrome. Gut 2006;55(5):649-54
108. Lim B, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006(4):CD005111
109. Gaylord SA, et al. Mindfulness training reduces the sever-ity of irritable bowel syndrome in women: Results of a ran-domized controlled trial. Am J Gastroenterol 2011;106(9): 1678-88
110. Zernicke KA, et al. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: A ran-domized wait-list controlled trial. Int J Behav Med 2012 May 23 [Epub ahead of print].
111. Naliboff BD, et al. Toward a biobehavioral model of vis-ceral hypersensitivity in irritable bowel syndrome. J Psychosom Res 1998;45(6):485-92
112. Verne GN, et al. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001;93(1):7-14
113. Halpert A, et al. Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare provid-ers: A national survey. Dig Dis Sci 2010;55(2):375-83
114. Halpert A, Godena E. Irritable bowel syndrome patients' perspectives on their relationships with healthcare provid-ers. Scand J Gastroenterol 2011;46(7-8):823-30
115. Bodenheimer T, et al. Patient self-management of chronic disease in primary care. JAMA 2002;288(19):2469-75
116. Von Korff M, et al. Collaborative management of chronic illness. Ann Intern Med 1997;127(12):1097-102